J&J dumps a failed PhI­II an­tibi­ot­ic pro­gram picked up in Acte­lion buy­out

J&J is wash­ing its hands of the Phase III Clostrid­i­um dif­fi­cile-as­so­ci­at­ed di­ar­rhea pro­gram for the an­tibi­ot­ic cada­zol­id.

The phar­ma gi­ant ob­tained rights to the an­tibi­ot­ic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER